Doximity, Inc. - DOCS STOCK NEWS

Doximity (NYSE: DOCS) reported strong fiscal Q2 2025 results with revenue reaching $136.8 million, up 20% year-over-year. The company demonstrated significant financial growth with net income increasing 44% to $44.2 million and adjusted EBITDA growing 41% to $76.1 million. Operating cash flow surged 430% to $68.3 million. The platform achieved record usage with over 600,000 unique active prescribers. For Q3 FY2025, Doximity expects revenue between $152-153 million and adjusted EBITDA of $83-84 million, while updating full-year guidance to revenue of $535-540 million and adjusted EBITDA of $274-279 million.

Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company will be represented by Nate Gross, co-founder and chief strategy officer, and Anna Bryson, chief financial officer, who will deliver a presentation on Thursday, November 21, 2024, at 11:30 a.m. GMT (6:30 a.m. ET).

Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has announced it will release its fiscal 2025 second quarter financial results on November 7, 2024, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. Interested parties can access the live audio webcast on Doximity's Investor Relations page at https://investors.doximity.com/ before the call. A replay of the webcast will be available on the website following the event.

Mendaera, a Silicon Valley-based healthcare technology company, has secured $73 million in Series B funding led by Threshold Ventures. The company is developing a handheld robotic interventional platform to address healthcare provider shortages and rising costs in mainstream medical procedures.

Mendaera's platform combines robotics, AI, real-time imaging, and virtual connectivity to improve quality and workforce productivity in common procedures like biopsies, organ and vascular access, and pain management interventions. The funding will be used to complete development of the robotic technology, accelerate AI and connectivity capabilities, and begin clinical introduction.

The company aims to enhance patient experience, increase access to high-quality care, reduce overall costs, and improve healthcare provider satisfaction by making advanced technologies more accessible across specialties and sites of service.

Doximity (NYSE: DOCS) reported strong fiscal 2025 Q1 results, with total revenue up 17% year-over-year to $126.7 million. The company saw significant growth in profitability, with net income increasing 46% to $41.4 million and adjusted EBITDA rising 42% to $65.9 million. Doximity's CEO highlighted record engagement, with 590,000 unique providers using their AI, telehealth, messaging, and scheduling tools. The company's non-GAAP net income margin improved to 44.1% from 37.5% year-over-year. For Q2 FY2025, Doximity expects revenue between $126.5-$127.5 million and adjusted EBITDA of $62.5-$63.5 million. The full-year FY2025 guidance projects revenue of $514-$523 million and adjusted EBITDA of $248.5-$257.5 million.

Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has announced that it will release its fiscal 2025 first quarter financial results on August 8, 2024, after the market closes. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. Interested parties can access the live audio webcast on Doximity's Investor Relations page at https://investors.doximity.com/ before the call. A replay of the webcast will be available on the website following the call.

Doximity, a leading digital platform for U.S. medical professionals, announced that CEO Jeff Tangney will present at the William Blair 44th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 5, 2024, at 2:00 p.m. Central Time. This event provides Doximity an opportunity to showcase its growth strategies and business developments to potential investors and stakeholders.

Doximity's 2024 Physician Compensation Report reveals a 5.9% increase in average physician compensation in 2023, following a 2.4% decline the previous year. The report highlights a 23% gender wage gap, with male physicians earning nearly $102,000 more than female physicians. Additionally, 81% of physicians feel overworked, with 59% considering employment changes, including early retirement. The physician shortage continues to impact 88% of respondents, with 86% expressing concern over the healthcare system’s ability to care for an aging population.

Doximity (NYSE: DOCS) announced their Q4 and Fiscal Year 2024 financial results. For the fiscal year, total revenues reached $475.4 million, a 13% increase year-over-year, and net income grew by 31%. Q4 revenues were $118.1 million, showing a 6% increase. Adjusted EBITDA for the fiscal year rose by 25%, and net income margins improved from 26.9% to 31%. The company reported a diluted net income per share for the fiscal year of $0.72, up from $0.53. Doximity also introduced a $500 million stock repurchase program. The company's financial outlook for fiscal year 2025 includes revenues between $506 million and $518 million, and adjusted EBITDA between $238 million and $250 million.